3 ASX Penny Stocks With Over A$90M Market Cap

The Australian share market is experiencing a challenging period, with a recent downturn marking its seventh consecutive day of declines. Amidst these broader market movements, penny stocks remain an intriguing option for investors interested in companies that are smaller or less established but potentially offer significant value. While the term “penny stocks” may seem outdated, it still represents an area where investors can find opportunities by focusing on those with strong financials and promising growth potential.

Top 10 Penny Stocks In Australia

Click here to see the full list of 387 stocks from our ASX Penny Stocks screener.

Let’s review some notable picks from our screened stocks.

Simply Wall St Financial Health Rating: ★★★★★★

Overview: LTR Pharma Limited is a clinical-stage pharmaceutical company focused on researching and developing an intranasal spray for treating erectile dysfunction in Australia, with a market cap of A$92.71 million.

Operations: The company generates revenue of A$1.13 million from its Medical Research and Development segment.

Market Cap: A$92.71M

LTR Pharma Limited, with a market cap of A$92.71 million, is focused on developing an intranasal spray for erectile dysfunction. Despite its clinical-stage status and being pre-revenue with earnings below US$1 million, the company remains debt-free and has short-term assets significantly exceeding liabilities. However, it faces challenges as losses have increased at 41.6% annually over the past five years, and the management team is relatively inexperienced with an average tenure of 1.4 years. The company reported a net loss of A$5.76 million for H2 2025 but maintains a cash runway exceeding three years if current cash flow trends persist.

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Sigma Healthcare Limited is a retail pharmacy franchisor and pharmaceutical wholesaler and distributor serving community pharmacies in Australia, with a market cap of A$32.32 billion.

Operations: The company generates its revenue from the healthcare segment, amounting to A$9.55 billion.

Market Cap: A$32.32B

Sigma Healthcare Limited, with a market cap of A$32.32 billion, has demonstrated strong financial performance in recent periods. The company reported significant sales growth to A$5.51 billion for the half year ending December 2025, alongside a net income increase to A$379.82 million. Despite its earnings growth slowing to 12% over the past year compared to its five-year average of 30.8%, Sigma maintains a satisfactory net debt-to-equity ratio of 13%. Its short-term assets cover both short and long-term liabilities comfortably, and interest payments are well-covered by EBIT at 13.2 times coverage, indicating robust financial health despite some management and board inexperience concerns.

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Service Stream Limited is an Australian company involved in the design, construction, operation, and maintenance of infrastructure networks across the telecommunications, utilities, and transport sectors with a market cap of A$1.22 billion.

Operations: The company’s revenue is primarily derived from its Telecommunications segment at A$1.08 billion, followed by Utilities at A$1.01 billion, and Transport contributing A$162.24 million.

Market Cap: A$1.22B

Service Stream Limited, with a market cap of A$1.22 billion, exhibits mixed financial performance as a penny stock. Recent earnings for the half year ended December 31, 2025, show revenue of A$1.14 billion and net income of A$26.81 million, though both figures have declined from the previous year. Despite this, the company remains debt-free and its short-term assets exceed liabilities significantly, indicating strong liquidity management. The dividend track record is unstable but has recently increased to A$0.03 per share fully franked for six months ending December 2025. While earnings growth has slowed recently to 0.6%, long-term profit growth remains robust at an average annual rate of 29.3% over five years.

Seize The Opportunity

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com